Protagenic therapeutics achieves first clinical safety milestone with its novel neuropeptide for the potential treatment of stress-related disorders

Company anticipates reporting complete phase i single dose results in april new york, ny / accesswire / february 13, 2024 / protagenic therapeutics, inc. (nasdaq:ptix), a biopharmaceutical innovator, announced a step forward in its mission to address stress-related neuro-psychiatric disorders. the company has completed the first dose escalation step in the phase i safety clinical trial for pt00114, its pioneering brain peptide compound.
PTIX Ratings Summary
PTIX Quant Ranking